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Abstract: Nocebo hyperalgesia has received sparse experimental attention compared to placebo 
analgesia. The aim of the present study was to investigate if personality traits and fear of pain 
could predict experimental nocebo hyperalgesia. One hundred and eleven healthy volunteers 
(76 females) participated in an experimental study in which personality traits and fear of pain 
were measured prior to induction of thermal heat pain. Personality traits were measured by the 
Big-Five Inventory-10. Fear of pain was measured by the Fear of Pain Questionnaire III. Heat 
pain was induced by a PC-controlled thermode. Pain was measured by a computerized visual 
analog scale. Stress levels during the experiment were measured by numerical rating scales. 
The participants were randomized to a Nocebo group or to a no-treatment Natural History 
group. The results revealed that pain and stress levels were significantly higher in the Nocebo 
group after nocebo treatment. Mediation analysis showed that higher levels of the Fear of Pain 
Questionnaire III factor “fear of medical pain” significantly increased stress levels after nocebo 
treatment and that higher stress levels were associated with increased nocebo hyperalgesic 
responses. There were no significant associations between any of the personality factors and the 
nocebo hyperalgesic effect. The results from the present study suggest that dispositional fear 
of pain might be a useful predictor for nocebo hyperalgesia and emotional states concomitant 
with expectations of increased pain. Furthermore, measurement of traits that are specific to pain 
experience is probably better suited for prediction of nocebo hyperalgesic responses compared 
to broad measures of personality.
Keywords: nocebo hyperalgesia, fear of pain, pain, emotions, personality, five-factor model 
of personality
Introduction
The nocebo hyperalgesic effect is defined as the increase in pain that follows the 
administration of an inert substance or procedure accompanied by suggestions of pain 
worsening.1 Placebo analgesia is the opposite of nocebo hyperalgesia and is the reduction 
of pain after treatment by an inert substance or procedure administrated along with sug-
gestions of pain relief. Nocebo hyperalgesia has received sparse scientific experimental 
attention compared to placebo analgesia.2 The lack of studies investigating the nocebo 
effect in pain has been attributed to ethical constraints, which limit the experimental 
possibilities in both clinical and experimental settings.3,4 Nocebo-related effects can be 
produced in clinical settings, that is, by inducing negative expectations via information 
about the side effects of medications and procedures, which in turn reduce the efficacy 
of analgesic treatment.5 However, the majority of studies on nocebo hyperalgesia have 
been performed in healthy volunteers. The existing studies on nocebo hyperalgesia 





have shown that negative emotional activation mediates the 
observed increase in pain6,7 and that nocebo manipulations 
may affect physiological systems such as the hypothalamic–
pituitary–adrenal axis,8 cerebral pain systems,9,10 and pain 
processing in the spinal cord.11 Anxiolytic drugs are capable 
of reversal of nocebo hyperalgesia, lending further support to 
the notion that emotional modulation is essential in nocebo 
hyperalgesic responding.7
Studies on placebo analgesia have shown that there 
is substantial individual variability in placebo analgesic 
responding,12 and it is likely that the same is true for nocebo 
hyperalgesia since nocebo hyperalgesia and placebo anal-
gesia share common mechanisms.13 The impact of global 
personality traits on placebo analgesia is unclear,14 but there 
is evidence that the personality trait, neuroticism, is associ-
ated with reduced placebo analgesia.15 Neuroticism is the 
tendency to experience negative emotions and cognitions 
that often accompany experiences of threat and punishment 
and is associated with elevated levels of anxiety, depres-
sion, anger, irritation, self-consciousness, rumination, and 
vulnerability.16 Negative emotions increase pain,17 and it 
is therefore reasonable to expect that individuals with high 
neuroticism are more prone to be affected by suggestions 
of pain increase compared to those with lower neuroticism. 
Personality traits, however, are general indicators of behav-
ior and not specifically predictive of pain experience. Traits 
that are pain specific might be equally or more predictive 
of pain experience than general personality traits. One such 
trait is fear of pain.18 Fear of pain refers to the dispositional 
tendency to react with negative emotions to pain and in the 
anticipation of pain.18 High levels of fear of pain are shown 
to decrease placebo analgesic responses.12,19 To date, no 
previous experimental study has examined the impact of 
personality or fear of pain in nocebo hyperalgesia.
In the present study, we measured global personality traits 
and fear of pain in healthy volunteers before induction of 
nocebo hyperalgesia in order to investigate their impact on 
the nocebo effect. We hypothesized that increased levels of 
the personality trait, neuroticism, would be associated with 
increased nocebo hyperalgesia. Likewise, based on previous 
findings that link increased fear of pain to reduced placebo 
analgesia, we expected that higher levels of fear of pain 
would be associated with higher levels of nocebo responses 
in pain. Finally, we expected that higher levels of both fear 
of pain and neuroticism would increase subjective negative 
emotional states after administration of nocebo treatment and 
thereby mediate the effect of neuroticism and fear of pain 
on the nocebo effect.
Methods
subjects
One hundred and twenty healthy volunteers between the 
age of 19 and 38 were recruited by an advertisement at the 
University of Tromsø, Norway. Due to missing pain data in 
four subjects and missing questionnaire data in five subjects, 
111 participants (female: n=76; mean age =22.21, standard 
deviation =3.10) were included in the statistical analyses. 
Exclusion criteria were current or previous severe disease 
(including chronic pain), pregnancy, cutaneous injuries on the 
arms and hands, and use of prescription medication (with the 
exception of oral contraceptives). All participants signed an 
informed consent form that stated they had no medical history 
of any serious diseases or injuries. All volunteers received a 
gift certificate worth 200 Norwegian Kroner. The study was 
approved by the Regional Committee for Medical Research 
Ethics, Region North, Project no 402/2012.
Design
A two group (Natural History, Nocebo) × three trials (Pre-
test, Posttest 1, Posttest 2) mixed design was used in the 
experiment. Four psychology students (two males and two 
females) with extensive experience with experimental labo-
ratory work conducted the experiment. The experimenters 
were not informed of which group the subjects belonged to 
until after the pretest. After the pretest, the experimenters 
opened an envelope that stated whether the participant should 
receive the nocebo treatment or the no-treatment condition 
(Natural History group).
Group alignment was randomized by an algorithm at 
 RANDOM.ORG.20 Calculations of group size were based 
on data from a previous study6 in which mean differences 
between the Nocebo groups and the Natural History group 
were between 7 mm and 11 mm on a 100 mm visual analog 
scale (VAS). Expected standard deviation in the sample 
was 16 VAS points. By including 50 participants in each 
group and using an alpha of 5% with two-tailed testing, a 
power estimate of 87% was calculated. To ensure power in 
the analyses when assuming a loss of data of ∼10% due to 
missing scores, experimenter error, etc, we recruited a total 
of 120 participants.
Pain stimuli
Pain was induced by contact with heat stimuli (30×30 mm 
aluminum contact thermode, [Pathway, Medoc, Israel]) 
applied to the right volar forearm. The thermode had a 
baseline temperature of 32°C when applied to the arm. The 
duration of the pain stimuli was 20 seconds with a plateau 
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for ∼16 seconds at 47°C in both the pretest and the posttests. 
The thermode rise/fall rate was 10°C/second.
Questionnaires
Personality was measured with the Big-Five  Inventory-10 
(BFI-10).21 The BFI-10 is an abbreviated version of the 
BFI-44,22 which measures the five-factor model of  personality. 
The BFI-10 is considered to be a valid and reliable mea-
sure of the five-factor model of personality.23 The five 
 factors are Extraversion, Agreeableness, Conscientious-
ness, Neur oticism, and Openness. The BFI-10 is scored on 
a 5-point Likert scale.
Fear of pain was measured with the Norwegian version 
of the Fear of Pain Questionnaire III (FPQ-III).12,19,24 FPQ-III 
consists of three subscales designed to tap fear related to 
severe pain (eg, breaking your arm), minor pain (eg, getting a 
paper cut in your finger), and medical pain (eg, having a blood 
sample drawn with a hypodermic needle). Each subscale con-
sists of ten items. Each item is scored on a 5-point Likert scale. 
Previous studies have demonstrated good internal consistency 
for the measure and good test–retest reliability.18,25
Pain and negative emotional states 
measurements
During each pain stimulus, the participants reported their pain 
intensity on a computerized visual analog scale (COVAS; 
Medoc, Israel) ranging from 0 to 100, where 0 represented “no 
pain” and 100 represented the “most intense pain imaginable”. 
The mean of the continuous pain rating during the stimuli was 
used as the pain score for each subject in each trial. Subjective 
stress was measured by two adjective pairs, similar to those 
used in previous studies,12,26,27 from the Norwegian transla-
tion of the Short Adjective Check List.28 The adjective pairs 
were tense-relaxed and nervous-calm. The adjective pairs 
were converted to numerical rating scales, where a score of 
zero indicated complete relaxation/calmness and a score of 
ten indicated maximum tension/nervousness. The stress score 
was expressed as the mean score for the two adjective pairs. 
Stress measures were obtained before the pretest, immediately 
after the administration of the nocebo cream, and immediately 
after the posttest.
nocebo cream
The university hospital pharmacy at the University Hospital 
of Northern Norway produced 100-mL tubes of nocebo cream 
(E45 Cream; Crookes Healthcare, UK). All tubes were num-
bered according to a list of codes and had an identical design. 
The code list was created by the university hospital pharmacy 
and was kept by the supervisor of the study (PMA), who did 
not participate in the experimental work. We chose the E45 
cream as the nocebo cream based on its similarities to local 
anesthetic creams in color, odor, and consistency. A dose of 
3 g of nocebo (E45) was used for each participant, similar 
to a previously published study.6
Procedure
The experiment took place in a laboratory shielded from 
sound and electricity where a constant temperature of 20°C 
was maintained. Upon arrival at the laboratory, the par-
ticipants signed an informed consent form. The participants 
received written information together with the consent form 
stating that the aim of the study was to test the physiological 
and psychological effects of a medical cream on heat pain. 
The participants were informed that they would receive a 
cream that increased pain or no treatment during the pain 
stimulation (Natural History group). The participants did not 
know what treatment they received or whether they partici-
pated in the control group until after the pretest.
After the experimenter received the signed consent, each 
participant was seated on a comfortable chair inside the 
cubicle. Then, the experimenters instructed the participant 
on how to use the COVAS and attached the thermode to 
the volar right forearm, at the dermatome corresponding 
to C8. Subsequently subjective stress was measured. Each 
participant then received a pain stimulus at 46°C for 5 sec-
onds duration prior to the pretest to reduce novelty of the 
heat pain experience.
After a 2-minute break, the experimenter started the 
first pain stimulation (pretest). Following the pretest, the 
experimenter delivered information regarding the cream, 
followed by application of the cream to a 5×5 cm location 
on the right volar forearm. The instructions for the cream 
were as follows: the Nocebo group was told, “The cream that 
will be applied to your arm increases the effect of the heat 
pain and you will feel more pain after the application. The 
substance in this cream is used in many medical remedies. 
Even though the pain feels more intense, the cream will not 
inflict any burn wounds”. In the Natural History condition, no 
cream was applied and no information regarding medication 
was given. During the break, the participants in the Natural 
History group were told to relax for a few minutes and to 
wait for the procedure to continue.
Following a 20-minute application period, subjective 
stress was measured. Subsequently, the thermode was again 
attached to the forearm 1 cm below the site of the thermode 
stimulation in the pretest to avoid possible lesion-related 





hyperalgesia, and the experimenter initiated the last two pain 
stimulations (posttests). The interval between the posttests 
was 2 minutes. After the last posttest, the final subjective 
stress measurement was obtained. The experimental proce-
dure had a total duration of ∼45 minutes. Figure 1 shows an 
overview of the procedure.
statistical analyses
All data were analyzed in SPSS Version 22 (IBM Corpora-
tion, Armonk, NY, USA). Tests for normality were performed 
by the Kolmogorov–Smirnov test. Due to violations of the 
assumptions of normally distributed data for pain, stress, 
and questionnaire data, we used nonparametric statistics 
for correlation analysis (Spearman correlations) and for the 
group by trial analysis (Friedman test). Pairwise Wilcoxon 
tests were used for comparisons of trials within groups. 
Mann–Whitney U-tests were employed to test the differ-
ences between the groups at each trial. A P-value ,0.05 
was considered significant for the analyses except the group 
comparisons in the repeated measures of pain and stress data 
where Bonferroni corrections were employed to correct for 
multiple comparisons (P,0.05/three trials [Pretest, Post-
test 1, Posttest 2] = P,0.0167). To test the hypothesis that 
fear of pain produces increased levels of stress that in turn 
causes increased pain, we performed a mediation analysis.29,30 
Mediation is present when a predictor (eg, fear of pain) affects 
an independent variable (eg, pain) indirectly through at least 
one intervening variable (eg, stress). A simple mediation 
model involves three steps that uses simple and multiple 
regressions: first, the dependent variable is regressed on the 
independent variable; second, the mediator is regressed on 
the independent variable; and finally, the dependent vari-
able is regressed on both the independent variable and the 
mediator.31 The mediation analysis employed in the present 
study is an advanced development of the above mentioned 
model that uses nonparametric bootstrapping for testing of 
indirect effects and allows the test of effects of covariates for 
the model. For further mathematical and technical details, 
see Preacher and Hayes.30
Results
Mean values for pain and stress are displayed in Tables 1 and 2, 
respectively. Table 3 displays descriptive data for BFI-10 and 
FPQ-III in the present sample. Table 4 shows the correlations 
between the FPQ factors and the personality factors. The 
Friedman test revealed that there were significant differences 
in pain ratings across trials (Pretest, Posttest 1, Posttest 2) 
in the Nocebo group (χ2(2)=73.71, P,0.001) and in the 
Natural History group (χ2(2)=25.96, P,0.001). Pairwise 
Wilcoxon tests displayed that pain scores were significantly 
different in both groups when comparing Pretest–Posttest 1, 
Pretest–Posttest 2, and Posttest 1–Posttest 2, all Z’s ,−2.74, 
all P’s ,0.001. Mann–Whitney U-tests were used for group 
comparisons in each trial (Pretest, Posttest 1, Posttest 2) 
and revealed that there was no significant group difference 
in the Pretest, but significantly higher pain reports in the 
Nocebo group compared to the Natural History group in 
both posttests (Table 1). When adjusting for multiple com-
parisons by Bonferroni corrections, all mean values in the 
posttests were still significantly higher in the Nocebo group 
compared to the Natural History group, and pain increased 
across time/posttests (Table 1). In the stress data, the Fried-
man test showed that there were significantly different levels 
of stress across trials in the Nocebo group (χ2(2)=15.75, 
P,0.001) and in the Natural History group (χ2(2)=54.45, 
P,0.001). Pairwise Wilcoxon tests revealed that stress was 
higher in both posttests (both Zs ,−3.54, both Ps ,0.001) 
compared to the pretest in the Nocebo group but that there 
was no difference in stress when comparing the posttests in 
the Nocebo group (Z=−0.63, P=0.52). In the Natural History 
group, stress reports were higher in both posttests compared 
to the pretest (both Zs ,−5.2, both Ps ,0.001), but there was 
no significant difference between the posttests (Z=−0.34, 




















20 minutes break after
application of the cream
Figure 1 Overview of the experimental procedure.
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the Nocebo group were significantly higher in both posttests 
compared to the Natural History group when considering the 
Bonferroni-adjusted P-value of 0.0167 (Table 2).
The effect of fear of pain on the nocebo hyperalgesic effect 
was tested by mediation analysis30 with the change in pain 
(pretest−posttest) as the dependent variable and the change 
in stress (pretest−posttest) after the nocebo manipulation as 
the mediator. Before the mediation analysis, we performed 
a partial correlation analyses in each group to display the 
association between the change in pain and the three fac-
tors in FPQ-III and the five personality factors measured by 
the BFI-10. The control variables for the partial correlation 
were sex and age. Contrary to our hypothesis, there was no 
significant association between any of the personality factors 
and the change in pain in the Nocebo or the Natural History 
group. The only significant association in the Nocebo group 
was the correlation between the FPQ factor “fear of medical 
pain” and the change score in the Nocebo group (r=−0.29, 
P=0.03). In the Natural History group, the only significant 
correlation was between the FPQ factor “fear of medical 
pain” and the pain change score (r=−0.42, P=0.003). Thus, 
“fear of medical pain” was the only pain-related personality 
trait that was used as a dependent variable in the mediation 
models.
The mediation analysis30 for the Nocebo group revealed 
that there was a direct effect of “fear of medical pain” on the 
change score in pain (B=−0.47, t=−2.99, P=0.004).
The total effect of “fear of medical pain” on pain change 
when controlling for sex and age was significant (B=−0.35, 
t=−2.17, P=0.03). The change in reported stress mediated 
the change in pain (nocebo effect), shown by the effect 
of “fear of medical pain” on the change in stress (B=0.08, 
t=2.06, P=0.04) and by the effect of stress change on pain 
change (B=1.50, t=2.73, P=0.008). The covariate sex was 
significant, showing that females reported a higher nocebo 
effect compared to males (B=7.21, t=3.03, P=0.004). There 
was no effect of the covariate age (P=0.55). The explained 
variance for the whole model was 32% (R2=0.32). Figure 2 
shows an overview of the mediation model in the Nocebo 
group. When performing the same mediation model on the 
Natural History group, no significant mediation effects were 
found, and the relation of “fear of medical pain” to stress 
change was nonsignificant (B=0.03, t=0.77, P=0.43).
Discussion
In line with our hypothesis, we found a significant asso-
ciation between increased levels of fear of medical pain 
and nocebo hyperalgesia. On the other hand, our data 
did not support the hypothesis that the personality trait, 
neuroticism, had an impact on reported pain increase after 
the nocebo manipulation. The mediation analysis showed 
that increased levels of the FPQ factor “fear of medical 
pain” increased stress levels after the nocebo treatment, and 
thereby potentiated the nocebo hyperalgesic effect (Figure 2). 
Table 2 stress reports in each trial and change scores
Group Nocebo group Natural History group
(N=57, 40 females) (N=54, 33 females)
Trial Mean/median SD Min–Max Mean/median SD Min–Max U P
Pretest 3.65/3 2.13 0 to 9 3.70/4 2.01 0 to 8 1,505 0.89
Posttest 1 2.56/2 1.35 1 to 9 1.82/1 1.86 0 to 7 2,128.5 ,0.001
Posttest 2 2.39/2 1.25 0 to 7 1.79/2 1.57 0 to 6 1,937 0.016
ΔPretest − Posttest 2 1.08/1 2.13 −5 to 6 1.65/2 1.98 −2 to 8 1,207.5 0.045
Notes: P-values denote the difference between the groups as shown by the Mann–Whitney test. Δ = change score (Pretest − Posttest 2). n=111.
Abbreviations: sD, standard deviation; Min, minimum; Max, maximum; U, Mann–Whitney U-test.
Table 1 Pain ratings in each trial and change scores
Group Nocebo group Natural History group
(N=57, 40 females) (N=54, 33 females)
Trial Mean/median SD Min–Max Mean/median SD Min–Max U P
Pretest 37.04/36 18.92 10 to 80 40.43/35.5 21.02 10 to 89 1,565 0.88
Posttest 1 60.20/62 19.66 20 to 96 48.37/48 21.05 7 to 98 2,183 ,0.001
Posttest 2 53.16/49 20.21 14 to 98 36.97/28.5 20.73 7 to 96 2,368 ,0.001
ΔPretest − 
Posttest 2
−16.13/−14 9.85 −36 to −8 5.73/1.5 8.33 −8 to 32 55.5 ,0.001
Notes: P-values denote the difference between the groups as shown by the Mann–Whitney test. Δ = change score (Pretest − Posttest 2). n=111.
Abbreviations: sD, standard deviation; Min, minimum; Max, maximum; U, Mann–Whitney U-test.





Previous studies have suggested that increased level of 
negative emotions is central for nocebo hyperalgesia to 
occur,3,6 and the results support this by showing that verbal 
suggestions of pain increase heighten negative emotional 
states, which in turn increase pain.32 The lack of association 
between personality traits and nocebo responding is similar 
to findings from several placebo analgesic studies in which 
the relation between placebo effects and personality factors 
is vague or absent.14 Nonetheless, some studies have found 
an effect of specific traits,15,33,34 and studies on this topic with 
larger samples are warranted.
Our finding that “fear of medical pain” predicted nocebo 
hyperalgesia and that neuroticism did not, supports the notion 
that the placebo and nocebo effects are modality-specific,35 
due to the fact that the FPQ-III is a measure specifically for 
pain and settings involving pain. It may therefore be difficult 
to relate nocebo effects in pain to superordinate personality 
traits measured by the five-factor model. In line with the 
principles of trait activation, which states that the activa-
tion/expression of a trait requires arousal by trait-relevant 
situational cues, “fear of medical pain” appears to tap 
emotional response patterns related to fear and anxiety in a 
pain-laboratory setting and possibly also in a clinical medical 
setting in which pain is anticipated. The other two factors 
on the FPQ-III were not related to the change in pain after 
nocebo manipulation in the present study. Both the factors 
“fear of minor pain” and “fear of severe pain” might represent 
pain situations that have less relevance as compared to the 
experimental setting that was used in the present study.
The present experiment was not designed to test for sex 
differences in the nocebo hyperalgesic response, but the 
results showed that females reported higher pain after the 
nocebo treatment compared to males. A previous study36 
has found similar sex differences in nocebo responding in 
nausea, and others have suggested that pain-related anxiety 
might be higher in females.37 Future studies could further 
investigate possible sex differences in nocebo hyperalgesia. 
One possibility of nocebo-related sex differences is the 
interaction of sex- and pain-related genetic expressions that 
in clinical studies have been shown to affect pain levels in 
chronic pain conditions.38 A limitation in our experimental 
design is the lack of a group that received placebo cream 
without suggestions of any change in pain. The administra-
tion of medications itself may cause elevations in stress, and 
a group that received reduced or no information about the 
effect of the cream may have provided the opportunity to 
separate the stress induced by the nocebo information from 
the stress induced by the treatment itself.
Our results suggest that dispositional fear of pain might 
be useful in predicting nocebo hyperalgesic responding and 
the negative emotional states that contribute to the vari-
ability in these responses. Finding predictors for nocebo 
hyperalgesia is important since in clinical practice, nocebo 
responses are probably at least as important as placebo.39 Fear 
and anxiety toward medical procedures are associated with 
Table 4 spearman correlations between the factors of the Fear of Pain Questionnaire iii (FPQ-iii) and the factors of the Big-Five 
















FPQ minor pain 0.14
FPQ medical pain 0.13 0.54**
BFi-10 extraversion 0.007 −0.13 −0.02
BFi-10 agreeableness 0.35** −0.20* −0.19* 0.08
BFi-10 conscientiousness 0.29** −0.16 −0.20* 0.15 0.51**
BFi-10 neuroticism 0.12 0.34** 0.31** −0.23* −0.17 −0.22*
BFi-10 openness 0.19* −0.13 −0.17 −0.08 0.32** −0.004 −0.07
Notes: *P,0.05; **P,0.01; n=111. Bold values indicate significant correlations.
Table 3 Big-Five inventory-10 (BFi-10) and the Fear of Pain 
Questionnaire iii (FPQ-iii)
Measure Mean/median SD Min–Max U P
BFI-10 personality
extraversion 3.76/4 0.98 1.5–5 1,453 0.62
agreeableness 3.43/3.5 1.12 1–5 1,423 0.51
conscientiousness 3.47/3.5 0.97 1–5 1,230.5 0.08
neuroticism 2.91/3 1.03 1–5 1,421 0.50
Openness 3.47/3.5 1.04 1.5–5 1,170 0.07
FPQ-III
FPQ severe pain 33.62/35 8.05 7–50 1,267.5 0.12
FPQ minor pain 20.19/20 6.11 10–43 1,514.5 0.91
FPQ medical pain 24.91/26 5.97 11–44 1,246.5 0.11
Notes: P-values denote the difference between the nocebo group and the natural 
history group computed from Mann–Whitney test n=111.
Abbreviations: sD, standard deviation; Min, minimum; Max, maximum; U, Mann–
Whitney U-test.
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negative treatment outcome,40,41 and even reduced placebo 
responding.23 Furthermore, identification of patients with 
elevated levels of pain-related fear and anxiety might also aid 
medical professionals in performing adequate adaptions for 
the single patient in order to optimize treatment effects.
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Figure 2 Overview of the mediation analysis for the nocebo group. 
Notes: B = regression coefficient. Pain change = Pretest − Posttest 2.
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